Exploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis
Open Access
- 7 May 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5059
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive loss of motor neurons. Emerging evidence suggests a potential link between metabolic dysregulation and ALS pathogenesis. This study aimed to investigate the relationship between metabolic hormones and disease progression in ALS patients. A cross-sectional study was conducted involving 44 ALS patients recruited from a tertiary care center. Serum levels of insulin, total amylin, C-peptide, active ghrelin, GIP (gastric inhibitory peptide), GLP-1 active (glucagon-like peptide-1), glucagon, PYY (peptide YY), PP (pancreatic polypeptide), leptin, interleukin-6, MCP-1 (monocyte chemoattractant protein-1), and TNFα (tumor necrosis factor alpha) were measured, and correlations with ALSFRS-R, evolution scores, and biomarkers were analyzed using Spearman correlation coefficients. Subgroup analyses based on ALS subtypes, progression pattern of disease, and disease progression rate patterns were performed. Significant correlations were observed between metabolic hormones and ALS evolution scores. Insulin and amylin exhibited strong correlations with disease progression and clinical functional outcomes, with insulin showing particularly robust associations. Other hormones such as C-peptide, leptin, and GLP-1 also showed correlations with ALS progression and functional status. Subgroup analyses revealed differences in hormone levels based on sex and disease evolution patterns, with male patients showing higher amylin and glucagon levels. ALS patients with slower disease progression exhibited elevated levels of amylin and insulin. Our findings suggest a potential role for metabolic hormones in modulating ALS progression and functional outcomes. Further research is needed to elucidate the underlying mechanisms and explore the therapeutic implications of targeting metabolic pathways in ALS management.Keywords
Funding Information
- Ministry of Research, Innovation and Digitization, CNCS-UEFISCDI (PN-III-P1-1.1-TE-2021-0960)
This publication has 106 references indexed in Scilit:
- Different patterns of spreading direction and motor neurons involvement in a cohort of limb‐onset amyotrophic lateral sclerosis patients from Southern Italy: Potential implication on disease course or progression?Brain and Behavior, 2023
- The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS)Brain and Behavior, 2021
- Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctionsNeurological Sciences, 2021
- Insulin Mediated Activation of PI3K/Akt Signalling Pathway Modifies the Proteomic Cargo of Extracellular VesiclesProteomics, 2017
- Flow-metabolism uncoupling in the cervical spinal cord of ALS patientsNeurological Sciences, 2017
- Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral SclerosisJAMA Neurology, 2015
- Awaji Criteria for the Diagnosis of Amyotrophic Lateral SclerosisArchives of Neurology, 2012
- Insulin in the Brain: Sources, Localization and FunctionsMolecular Neurobiology, 2012
- The Role of GLP-1 in Neuronal Activity and Neurodegeneration2010
- Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult ratNeuroscience, 1991